{"id":"a58db4b545dd","type":"article","url":"https://hartvaat.nl/2026/03/01/auteurs-reageren-pravastatine-bij-autosomaal-dominante-polycysteuze-nierziekte/","title":"Auteurs reageren: pravastatine bij autosomaal dominante polycysteuze nierziekte","title_en":"The authors reply","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["anemie-ckd"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01011-7/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01011-7/fulltext","authors":["Berenice Y. Gitomer","Anna Ostrow","Michel Chonchol"],"significance":5,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"The authors respond to comments on their randomised study of pravastatin for kidney disease outcomes in adults with early-stage autosomal dominant polycystic kidney disease, addressing methodological considerations and clinical implications.","created":"2026-07-03T10:25:14Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Reactie van de auteurs op commentaar bij hun gerandomiseerde studie over het effect van pravastatine op nierziekte-uitkomsten bij volwassenen met vroege ADPKD.","abstract_original":"We would like to thank the authors for their comments1 on our article, “A Randomized Controlled Trial Evaluated the Effect of Pravastatin on Kidney Disease Outcomes in Adult Patients with Early-Stage Autosomal Dominant Polycystic Kidney Disease.”2"}